- ADC Therapeutics (ADCT, Financial) unveils promising preclinical data for three antibody drug conjugates (ADCs).
- ADCT-242 exhibits robust antitumor activity in ovarian and non-small lung cancer models.
- ADCT-241 and HuB14-VA-PL2202 demonstrate synergy and effectiveness across various cancer types.
ADC Therapeutics (ADCT) has presented new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2025, showcasing the potential of three exatecan-based antibody drug conjugates (ADCs) targeting Claudin-6, PSMA, and ASCT2.
ADCT-242, targeting Claudin-6, showed potent antitumor activity in ovarian and non-small cell lung cancer models. The compound was well-tolerated in mice up to 150 mg/kg and in cynomolgus monkeys up to 40 mg/kg, indicating a promising therapeutic index.
Another ADC, ADCT-241, demonstrated effectiveness in prostate cancer models expressing PSMA. Notably, it showed synergistic effects when combined with the existing treatment enzalutamide and exhibited good tolerability in preclinical studies involving rats and cynomolgus monkeys.
HuB14-VA-PL2202, targeting ASCT2, also revealed substantial antitumor activity in both solid and hematological cancer cell lines. It was well-tolerated in cynomolgus monkeys, reinforcing ADC Therapeutics' leadership in developing ADCs to combat diverse cancer types.
As these studies remain in the preclinical phase, further research is required to evaluate these ADCs' efficacy and safety in human clinical trials.
